Beckman Coulter and Quidel announced a settlement agreement to end litigation that began in November 2017, following Quidel's acquisitions of the BNP Business from Alere.
Under the agreement, Beckman Coulter has obtained all rights of manufacture, distribution and sale of a BNP assay for Beckman Coulter analyzers, fully resolving the dispute. Quidel will continue to manufacture and supply some components to Beckman Coulter related to the assay, and Beckman Coulter will exclusively sell and manufacture to customers the TRIAGE BNP by Quidel under the brand name Access BNP. Quidel will receive $70-$75 million per year through 2029.
BNP is a protein biomarker secreted by the ventricular musculature in response to volume or pressure overload on the heart. The biomarker can be used in the diagnosis of heart failure and left ventricular dysfunction.
